Total company profitability achieved as clonoSEQ clinical adoption accelerates.
- The company achieved total profitability in Q3 2026 with Adjusted EBITDA of $14.3 million.
- clonoSEQ clinical test volume grew 46% year-over-year in the third quarter.
- New clinical guidelines and a new definition of cure in multiple myeloma mandate highly sensitive testing.
- The company announced plans to separate the MRD and Immune Medicine businesses by year-end 2026.
- Adaptive is winding down its research-use-only immunosequencing service to focus on data licensing.
A sharper focus yields total company profitability
Adaptive reached a major milestone in the third quarter of 2026 by achieving total company profitability ahead of expectations. The main story remains clonoSEQ, a test for minimal residual disease that detects tiny amounts of cancer left after treatment. MRD clinical volume grew 46% year-over-year, and the external environment is shifting forcefully in the company favor. Updated NCCN guidelines and a new International Myeloma Working Group definition of cure now effectively mandate the highly sensitive serial testing that clonoSEQ provides.
The bull case is exceptionally strong following Q3 2026. The core MRD business is growing rapidly and has validated its unit economics by driving the entire company to profitability. Adaptive has submitted a technical assessment to MolDX for a new maintenance bundle in multiple myeloma. If approved, this stands as a primary catalyst for average selling price expansion and recurring revenue.
The bear case centers on heavy product concentration and the risks of a complex transition. MRD testing accounted for 86% of revenue in the recent quarter. The planned separation of the Immune Medicine segment introduces near-term execution risk, uncertainty around the final structure, and questions about how to handle $345 million in convertible debt. There is also near-term pressure on realized average selling prices until the new maintenance bundle is secured.
Investors currently value the company largely for its MRD growth and newly proven profitability. A pending corporate restructuring and a minor reimbursement headline risk regarding erroneous preliminary data submitted to CMS require close monitoring.
Restructuring toward pure diagnostics and maintenance testing
Adaptive historically made money in two segments: MRD and Immune Medicine. MRD is the core business. It sells clonoSEQ testing to doctors who monitor blood cancers and to biopharma companies that use the test in drug studies. This diagnostic side has consistent growth, clear pricing, and recently pushed the entire company into profitability.
The Immune Medicine segment previously sold immunosequencing research services, data licensing, and discovery partnerships. However, in July 2026, the company decided to wind down its research-use-only pharma services to focus exclusively on its target discovery platform and data models.
The biggest structural change is the plan to separate these two segments entirely by the end of 2026. The goal is to let the profitable MRD business operate without funding early-stage Immune Medicine research.
The company relies heavily on clinical guidelines to drive test volume. Recent updates recommending testing at a sensitivity level uniquely provided by clonoSEQ give the company a powerful mandate to sell serial testing bundles to clinics.
What Adaptive sells
clonoSEQ for clinical care
clonoSEQ is the main product. It helps doctors detect and monitor tiny traces of cancer in multiple myeloma and other lymphoid cancers.
clonoSEQ for biopharma trials
Drug companies use clonoSEQ testing in studies to measure how well cancer drugs clear disease.
TCR discovery and antigen maps
Adaptive uses immune receptor data to connect T cells with the targets they recognize. This includes data licensing agreements with partners like Pfizer.
Adaptive Immunosequencing
This research-use service reads immune receptor data. The company is winding down this offering in the second half of 2026.
MRD takes over the mix
Based on internal management disclosures in Q3 2026, the Minimal Residual Disease segment accounted for 86% of total revenue. This makes clonoSEQ the primary value driver ahead of the planned separation.
What could go wrong
Execution of the corporate split
High impact · Medium oddsThe planned separation of the MRD and Immune Medicine segments by year-end 2026 is complex. It could incur high costs, distract management, or fail to find a viable path for the Immune Medicine assets.
clonoSEQ concentration
High impact · High oddsMRD made up 86% of recent quarterly revenue. That means one product line drives almost the whole company. Any slowdown in clonoSEQ volumes would severely damage the core business valuation.
Reimbursement and pricing pressure
Medium impact · Medium oddsErroneous PLA data submitted to CMS created near-term headline risk for preliminary rates. As testing frequency increases, there is also pressure on realized average selling prices until a new maintenance bundle is secured.
New debt burden
Medium impact · Medium oddsThe company issued $345 million in convertible notes in June 2026. This increases leverage before the separation is complete and could limit future cash flow flexibility.
In one breath
What does Adaptive Biotechnologies do?
Adaptive reads immune-system data and sells tests based on that data. Its main product is clonoSEQ, a cancer monitoring test for minimal residual disease.
Why is clonoSEQ important?
clonoSEQ helps detect very small amounts of cancer left after treatment. The business built around clonoSEQ drives the vast majority of company revenue.
Is the company splitting up?
Yes. In June 2026, Adaptive announced a plan to separate its MRD and Immune Medicine businesses by the end of 2026.
What happened to the immunosequencing service?
Adaptive announced in July 2026 that it is winding down its research-use-only immunosequencing offering to focus purely on target discovery and data models.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Adaptive Biotechnologies Corporation in Finn's Biotechnology industry ranking.

